Low-dose whole-body radiation before CAR T cell therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial adds a low dose of radiation to the entire body before CAR T cell therapy for patients with acute lymphoblastic leukemia. The goal is to see if this extra step helps the CAR T cells work better, without adding much extra discomfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute lymphoblastic leukemia (ALL) and are scheduled to get CAR T cell therapy.
- You are not planning to receive radiation to the brain and spine before CAR T therapy.
- You are in generally good health (able to care for yourself, up and about more than half the day).
- Your blood counts and organ function are within acceptable limits.
- If you have had hepatitis B or C, the virus must be under control or cured.
- You agree to use reliable birth control (if you or your partner can become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
This trial tests whether giving a low dose of radiation to the whole body before receiving CAR T-cell therapy helps the treatment work better for people with certain types of lymphoma or multiple myeloma that have come back or not responded to earlier treatments.
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.